Compare iShares MSCI China ETF (MCHI) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs ResMed Inc. — how do they compare? iShares MSCI China ETF trades at $54.03, while ResMed Inc. trades at $196.27 (market cap $28.81B). The key difference: ResMed Inc. pays a 1.21% dividend while iShares MSCI China ETF pays none. Which is the better fit depends on your goals.
| MCHI | RMD | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $66.99 | $293.73 |
52-Week Low | $50.48 | $182.82 |
Market Cap | — | $28.81B |
Enterprise Value | — | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $54.08, up 2.13% today, but technical indicators signal a bearish trend with moving averages showing sell pressure. The stock lacks key valuation metrics like P/E and P/S, and recent news highlights China's economic stimulus focus and AI sector growth, which could impact this China-focused ETF. Dividend activity is scheduled for mid-2026.
The outlook is cautious due to bearish technicals and macroeconomic risks from U.S.-China tensions, though AI-driven exports offer growth potential. Investors face value trap risks amid mixed analyst sentiment, requiring close monitoring of China's policy developments and corporate earnings for directional cues.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
